Shandong Weigao board approves new H share incentive scheme

Shandong Weigao Group Medical Polymer Company Limited has announced its board of directors has approved the proposed adoption of a new H share incentive scheme, referred to as the “2025 H Share Incentive Scheme.” This initiative aims to attract and retain eligible participants crucial to the group’s long-term growth, recognize past contributions, and encourage future performance to enhance company and shareholder value.

The scheme will also serve to bolster the company's long-term remuneration strategy and align participant interests with those of the company and its shareholders, promoting overall performance across financial, business, and operational aspects of the group. The 2025 H Share Incentive Scheme is intended to be funded by existing H shares and/or treasury shares of the company.

The adoption of the 2025 H Share Incentive Scheme and related matters are subject to approval by shareholders at an extraordinary general meeting, which will be convened in due course. A circular containing detailed terms of the scheme will be published in accordance with listing rules.